Response to Nafziger and Bertino [2]

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 380-

  Kaneshiro, Y ^a   Oda, Y ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CORTICOSTEROID; CYTOCHROME P450 3A; MIDAZOLAM;

ANESTHESIA INDUCTION; AREA UNDER THE CURVE; BONE NECROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; HUMAN; IMMUNOBLOTTING; LETTER; LIVER BLOOD FLOW; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 34548692965     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100323     Document Type: Letter

References (10)

1. Lee, L.S., Bertino, J.S., Jr & Nafziger, A.N. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J. Clin. Pharmacol. 46, 229-234 (2006).
2. Kim, J.S. et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol. 42, 376-382 (2002).
3. Kaneshiro, Y. et al. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin. Pharmacol. Ther. 80, 396-402 (2006).
4. Lin, Y.S. et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11, 781-791 (2001).
5. Chaobal, H.N. & Kharasch, E.D. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther. 78, 529-539 (2005).
6. Tateishi, T. et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin. Pharmacol. Ther. 69, 333-339 (2001).
7. Thummel, K.E. et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271, 557-566 (1994).
8. Thummel, K.E. et al. Use of midazolam as a human cytochrome P450 3A probe: 1. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271, 549-556 (1994).
9. Thummel, K.E. & Wilkinson, G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
10. Backman, J.T., Kivisto, K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998).